For a Chinese plasma product, reaching the Middle East is two questions. First, whether China will export it — covered in the export regulations and market-entry guide. Second, which authority in the region will register and admit it. This page is about the second question.
The regulatory landscape
There is no single Middle East regulator. Three paths matter for a plasma-derived product or vaccine:
| Market | Authority | What it requires |
|---|---|---|
| Saudi Arabia | Saudi Food and Drug Authority (SFDA) | National registration + import licence, batch-by-batch sampling and testing for blood derivatives and vaccines |
| United Arab Emirates | Ministry of Health and Prevention (MOHAP) / Dubai Health Authority (DHA) | National registration, local agent required |
| GCC (multi-country) | GCC Central Drug Registration (GCC-DR) | A single central registration recognised across member states, with national marketing authorisation still issued locally |
The GCC-DR route is attractive because it files once for several countries, but it does not replace national licensing — a Saudi or UAE marketing authorisation and import licence are still issued by the national authority.
The constraint that defines the region
Across the Gulf, vaccines and human plasma derivatives are treated differently from ordinary pharmaceuticals: every batch is sampled and tested before release. In Saudi Arabia, samples from each consignment are drawn at the port and delivered to the SFDA laboratory within 48 hours, and the batch is not released for use until the test result is issued. This is a standing condition, not a first-import formality.
Two further Saudi conditions shape the logistics: products must be supplied directly from the manufacturer (import from free zones is not permitted), and the manufacturer must enter each batch into the SFDA's batch-release system. For a Chinese exporter, this means the cold-chain and the batch documentation have to be correct on the first shipment — there is no light-touch entry.
The dossier the Chinese side must supply
The core file a Chinese exporter must supply is the same one described in the general market-entry guide, structured for the target authority:
- Certificate of Pharmaceutical Product — the WHO-format status evidence, authenticated in the country of origin.
- The drug approval number, verifiable on the NMPA database.
- The batch release certificate — that the specific lot was state-released.
- GMP evidence for the manufacturing site.
- A certificate of analysis for the specific batch, signed by the factory quality manager.
- The export mandate or authorisation naming the exporter.
The sequence, end to end
| Step | What happens | Who does it |
|---|---|---|
| 1. Confirm exportability | Product is finished, registered, batch-released — not source plasma | Exporter + manufacturer |
| 2. Appoint the local agent | A locally licensed marketing authorisation holder per target market | Importer side |
| 3. Register | National registration, or GCC-DR central registration plus national MA | Local holder |
| 4. Import licence | National import licence (e.g. SFDA, via the GHAD system) | Licensed importer |
| 5. Ship & test | Direct-from-factory shipment, batch sampled and tested before release | Licensed importer + authority |
How a Chinese export agent fits in
Wanyoda's role is the export side of this sequence. We hold the written export mandates from NMPA-licensed manufacturers and coordinate the product file — approval number verification, CPP, batch release, GMP evidence and the signed CoA — so the local holder receives a complete, filing-ready dossier and a batch file that matches what the authority will test. We do not hold the national registration, because each market requires a locally licensed holder.
What this means in practice: the fastest Gulf entry is one where the export-side batch documentation is already exact — batch number, CoA and release certificate all aligned — because the region's batch-testing regime leaves no room to fix paperwork after the shipment has sailed.
The Middle East constraint that matters most: blood derivatives and vaccines are tested batch by batch. Exact batch documentation on day one is not a nice-to-have — it is the difference between a cleared consignment and a held one.
Frequently asked questions
Which authority regulates blood product imports in Saudi Arabia?
The Saudi Food and Drug Authority (SFDA) registers medicines and biologicals and licenses their import. Blood derivatives and vaccines are subject to batch-by-batch sampling and testing at the SFDA laboratory before release.
Is a GCC-wide registration available?
Yes, the GCC Central Drug Registration (GCC-DR) offers a single registration recognised across member states, but national authorities still issue the local marketing authorisation and import licence. Saudi Arabia and the UAE remain the two largest entry points.
Can a Chinese exporter hold the Middle East registration?
No. Each market requires a locally licensed agent or marketing authorisation holder. The Chinese exporter supplies the product file, and the local holder files the dossier.
Why does every batch of blood product get sampled in Saudi Arabia?
Saudi regulation requires samples from every batch of vaccine or human plasma derivative to be drawn and tested at the SFDA laboratory, with documents submitted within 48 hours of clearance, before the batch is released for use.
Where to go next
- The destination-by-destination guide — how the Middle East compares to the Philippines and India.
- How to import into India — the CDSCO path, for comparison with the GCC regime.
- Certificate of Pharmaceutical Product — the document every dossier turns on.
- Batch release: what actually gates a shipment — why the manufacturer cannot release its own product.
- Open territories — where we are actively appointing partners.